Navigation Links
Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry

NEW HAVEN, Conn., Oct. 7 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of multi-antibiotic resistant infections, today announced that Rib-X Co-Founder and Chair of the Scientific Advisory Board, Sterling Professor of Molecular Biophysics and Biochemistry at Yale University and a Howard Hughes Medical Institute Investigator, Thomas A. Steitz, Ph.D., has been awarded the Nobel Prize in Chemistry for 2009 by The Royal Swedish Academy of Sciences.

Dr. Steitz shares the prize with Venkatraman Ramakrishnan of the MRC Laboratory of Molecular Biology, Cambridge, United Kingdom, and Ada E. Yonath, Weizmann Institute of Science, Rehovot, Israel. All three were praised for their work on using "X-ray crystallography to map the position for each and every one of the hundreds of thousands of atoms that make up the ribosome." Dr. Ramakrishnan is also on Rib-X's Scientific Advisory Board.

"Rib-X would like to extend its congratulations to Drs. Steitz, Ramakrishnan and Yonath on receiving the most esteemed award for scientific endeavors and accomplishments," said Dr. Susan Froshauer, President and Chief Executive Officer, Rib-X. "As one of our co-founders, Dr. Steitz recognized the importance of the ribosome early on, and he continues to perform a valuable role to us as the Chair of the Scientific Advisory Board."

"I am excited by the prospect that our work on the structure of the ribosome and mechanisms of antibiotic binding is leading to potential new chemical classes which have the potential to treat a wide variety of multi-drug resistant bacterial infections," commented Dr. Steitz.

Dr. Peter Moore, Sterling Professor of Chemistry at Yale University and Dr. Harry Noller, Robert Louis Sinsheimer Professor of Molecular Biology at the University of California, Santa Cruz, also co-founders and part of Rib-X's Scientific Advisory Board, have worked closely with Dr. Steitz; together they received the Rosenstiel Award for Distinguished Work in Basic Medical Sciences for their research on the ribosome in 2001.

Rib-X was built on the extraordinary science of these founders and utilizes this award winning knowledge of the structure and function of the ribosome. Their hard work has yielded several distinctive new antibiotics that can be used for the treatment of multi-antibiotic resistant infections. These include three programs -- radezolid, Rx-04 and Rx-02 -- that are derived from Rib-X's proprietary discovery engine.

Radezolid is a late stage Phase 2 novel oxazolidinone designed to expand the bacterial spectrum and improve the utility of this class of antibiotics relative to the only other oxazolidinone marketed in the world, Zyvox® (linezolid). Additional programs include Rx-04, which employs a de novo approach to develop novel antibiotics that are active against multi-drug resistant Gram-negative bacteria and Rx-02, which is focused on engineering novel macrolides that have demonstrated activity against overcome known bacterial resistance mechanisms and have also demonstrated activity against methicillin-resistant Staphylococcus aureus.

Dr. Steitz, a Professor of Molecular Biophysics and Biochemistry at Yale University, was selected by the Nobel Prize Committee for his research on using X-ray crystallography to map the position for each and every one of the hundreds of thousands of atoms that make up the ribosome. Dr. Steitz focused on a subunit of the ribosome, which has proved to be a major target for antibiotics. By generating 3D models that show how different antibiotics bind to the ribosome, scientists can now develop new antibiotics.

About Thomas A. Steitz, Ph.D.

Born in Milwaukee, WI, Dr. Steitz received his Ph.D. in Molecular Biology and Biochemistry in 1966 from Harvard University. He was elected to the National Academy of Sciences in 1990. In 2001, Dr. Steitz together with Drs. Moore and Noller received the Rosenstiel Award for Distinguished Work in Basic Medical Sciences for their research on the ribosome. Currently, Dr. Steitz is the Sterling Professor of Molecular Biophysics and Biochemistry and a Howard Hughes Medical Institute Investigator at Yale University. His research in the field of protein and nucleic acid X-ray crystallography, including his recent work with Dr. Moore on the 50S ribosome structure has had wide-ranging impact in the global scientific community.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics, including radezolid, that can be used for the treatment of either community- or hospital-acquired infections. Delafloxacin (RX-3341) is a Phase 3-ready broad-spectrum fluoroquinolone with potent activity against quinolone-resistant Gram-positive bacteria, including methicillin-resistant S. aureus. Radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X as an oral/IV agent for treatment of serious Gram-positive infections, has completed two Phase 2 trials. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria, and the RCH-02 discovery program is focused on developing an IV/oral macrolide active against MRSA, multidrug-resistant Streptococcus pneumoniae and S. pyogenes. Both delafloxacin and radezolid are currently in late-stage clinical trials.

SOURCE Rib-X Pharmaceuticals, Inc.

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
6. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
7. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has ... it. Surviving Mesothelioma has just posted the findings on the website. Click here ... the cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, ... Table 1-1 ). More than 3.7 billion people under the age of 50 – ... according to WHO's first global estimates of HSV-1 infection . , "The data shocks ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by ... of issues that are presently affecting Americans. Dedicated to providing the world with a ... the subjects consumers focus on, one episode at a time. , In the ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to announce ... (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to ... of twelve colleges and universities in the state of California make the cut. CBD ...
Breaking Medicine News(10 mins):